Paper37598237
Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome.
Li F and 6 others. Sci Rep, 2023. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome. Papers, record 37598237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37598237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sjogren's Syndrome | Major topic |
| Lacrimal Apparatus | Major topic |
| Humans | |
| Adipose Tissue | |
| Patients | |
| Stem Cells |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36217186 | Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjögren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic). | Adv Rheumatol | 2022 | https://conductscience.org/library/papers/36217186 | PubMed |
| 2 | 34651000 | Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34651000 | PubMed |
| 3 | 31022578 | Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. | Clin Immunol | 2019 | https://conductscience.org/library/papers/31022578 | PubMed |
| 4 | 29737401 | Transplantation of adipose tissue-derived stem cells ameliorates autoimmune pathogenesis in MRL/lpr mice : Modulation of the balance between Th17 and Treg. | Z Rheumatol | 2019 | https://conductscience.org/library/papers/29737401 | PubMed |
| 5 | 32297483 | Update on disease pathogenesis, diagnosis, and management of primary Sjögren's syndrome. | Int J Rheum Dis | 2020 | https://conductscience.org/library/papers/32297483 | PubMed |
| 6 | 30452329 | Primary Sjögren's syndrome. | Lupus | 2018 | https://conductscience.org/library/papers/30452329 | PubMed |
| 7 | 36355371 | Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/36355371 | PubMed |
| 8 | 35958619 | Bioinformatics analysis of potential common pathogenic mechanisms for COVID-19 infection and primary Sjogren's syndrome. | Front Immunol | 2022 | https://conductscience.org/library/papers/35958619 | PubMed |
| 9 | 30762487 | Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. | Regen Med | 2019 | https://conductscience.org/library/papers/30762487 | PubMed |
| 10 | 31672775 | EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. | Ann Rheum Dis | 2020 | https://conductscience.org/library/papers/31672775 | PubMed |
| 11 | 29736200 | Adipose-derived mesenchymal stem cell-derived exosomes alleviate overwhelming systemic inflammatory reaction and organ damage and improve outcome in rat sepsis syndrome. | Am J Transl Res | 2018 | https://conductscience.org/library/papers/29736200 | PubMed |
| 12 | 24411404 | Outcome measures for primary Sjögren's syndrome: a comprehensive review. | J Autoimmun | 2014 | https://conductscience.org/library/papers/24411404 | PubMed |
| 13 | 35949326 | Adipose-derived stem cells postpone the progression of Sjögren's syndrome by upregulating the Hippo signaling pathway. | Exp Ther Med | 2022 | https://conductscience.org/library/papers/35949326 | PubMed |
| 14 | 28874101 | The Role of Cellular Proliferation in Adipogenic Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells. | Stem Cells Dev | 2017 | https://conductscience.org/library/papers/28874101 | PubMed |
| 15 | 29687384 | Adipose-Derived Stromal Vascular Fraction Cells and Platelet-Rich Plasma: Basic and Clinical Implications for Tissue Engineering Therapies in Regenerative Surgery. | Methods Mol Biol | 2018 | https://conductscience.org/library/papers/29687384 | PubMed |
| 16 | 35803061 | Immunopathogenesis of Sjogren's syndrome: Current state of DAMPs. | Semin Arthritis Rheum | 2022 | https://conductscience.org/library/papers/35803061 | PubMed |
| 17 | 36007392 | Mesenchymal stem cell transplantation alleviates Sjögren's syndrome symptoms by modulating Tim-3 expression. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/36007392 | PubMed |
| 18 | 22563590 | American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. | Arthritis Care Res (Hoboken) | 2012 | https://conductscience.org/library/papers/22563590 | PubMed |
| 19 | 35063331 | Intra-articular injection of culture-expanded adipose tissue-derived stem cells for knee osteoarthritis: Assessments with clinical symptoms and quantitative measurements of articular cartilage volume. | J Orthop Sci | 2023 | https://conductscience.org/library/papers/35063331 | PubMed |
| 20 | 34796851 | Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. | Clin Exp Rheumatol | 2021 | https://conductscience.org/library/papers/34796851 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42067941 | Efficacy and safety of stem cell therapy for dry eye disease: a systematic review and meta-analysis. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/42067941 | PubMed |
| 41947170 | Innovative strategies for immune thrombocytopenia treatment: immunomodulatory mechanisms and clinical potential of mesenchymal stem cells. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/41947170 | PubMed |
| 41857438 | Treatment of Xerostomia with Mesenchymal Stem Cells - A Systematic Review and Meta-Analysis of Clinical Trials. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/41857438 | PubMed |
| 41210252 | Adipose-derived stem cells alleviate radiation-induced muscle fibrosis by promoting muscle regeneration. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41210252 | PubMed |
| 39941329 | The Differentiation and Regeneration Potential of ABCB5+ Mesenchymal Stem Cells: A Review and Clinical Perspectives. | J Clin Med | 2025 | https://conductscience.org/library/papers/39941329 | PubMed |
| 39934871 | Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/39934871 | PubMed |
| 39310092 | Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review. | Dent Rev (N Y) | 2024 | https://conductscience.org/library/papers/39310092 | PubMed |
| 38311916 | Mechanisms of Stem Cells and Their Secreted Exosomes in the Treatment of Autoimmune Diseases. | Curr Stem Cell Res Ther | 2024 | https://conductscience.org/library/papers/38311916 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| CD14 | 929 | PubTator's text mining | https://conductscience.org/library/genes/929 | NCBI Gene |
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD79A | 973 | PubTator's text mining | https://conductscience.org/library/genes/973 | NCBI Gene |
| ITGAM | 3684 | PubTator's text mining | https://conductscience.org/library/genes/3684 | NCBI Gene |
| NT5E | 4907 | PubTator's text mining | https://conductscience.org/library/genes/4907 | NCBI Gene |
| PTPRC | 5788 | PubTator's text mining | https://conductscience.org/library/genes/5788 | NCBI Gene |
| SPTAN1 | 6709 | PubTator's text mining | https://conductscience.org/library/genes/6709 | NCBI Gene |
| SSB | 6741 | PubTator's text mining | https://conductscience.org/library/genes/6741 | NCBI Gene |
| THY1 | 7070 | PubTator's text mining | https://conductscience.org/library/genes/7070 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37598237
GET https://conductscience.org/api/papers/v1/37598237/references?page=2